Net profits up 37% to HK$912 million with final dividend HK$0.05/share ; Results reaching historic high; Continuous achievements from innovations Results summary: Total revenue...

Net profits up 37% to HK$912 million with final dividend HK$0.05/share ; Results reaching historic high; Continuous achievements from innovations

Results summary:

  • Total revenue HK$4,181 million, representing an increase of 35.9%
  • Net profit HK$912 million, representing an increase of 37.2% year-on-year
  • Gross profit HK$2,606 million, gross profit margin up to 62.3%
  • The Board propose an increased final dividend of HK$0.05 per share

HONG KONG, CHINA – Media OutReach – March 13, 2019 – SSY Group Limited (“SSY”
or the “Company”; Stock Code: 2005.HK) and its subsidiaries (together, the
“Group”) presents the annual results of the Company for the year ended 31 December
2018 (“2018” or the “year”).

During the year, the Group achieved a revenue
of HK$4,181 million, representing an increase of 35.9% and the gross profit
margin increased by 3.6 percentage point compared to last year. The net profit
was HK$912 million, representing an increase of 37.2% compared with last year.
The Company put a greater effort into business development, making full use of
its dominances in variety, quality, cost and brand as well as coordinating the
development of end market. The Company also attracted sales and marketing
professionals to expand the clinical business development team, strengthen its
after-sales services and its market share. Production and sales of intravenous
infusion solutions, the Company
s leading
products, were thriving. During the year, sales volume reached 1,460 million
bottles/bags and upright soft bags achieved the most significant growth. The
proportion of sales of therapeutic infusion solutions began to rise, becoming
the main driver for the improvement of product mix.

The Board of directors proposed to pay a final
dividend of HK$0.05 per share for year 2018, together with interim dividend
HK$0.04 per share, total dividend HK$0.09 per share for whole year of 2018. The
total amount of dividend this year to be paid is HK$271 million, which
represented an increase of 31.7% compared to last year.

In 2018, sales volume of intravenous infusion
solutions reached 1,460 million bottles/bags, representing an increase of 12.5%
compared to last year. The number of major provincial markets with annual sales
exceeding RMB100 million increased to 14, laying a market foundation for the
s future expansion of its
new products. In addition to maintaining sustained growth in the domestic
market, the Group also steadily accelerated its international business. During
the year, foreign trade sales amounted to RMB114 million, representing an increase of
20.7%. Production and sales volume of small liquid injections products in
ampoule started to increase rapidly. In 2018, the sales exceeded RMB100 million
for the first time, representing a year-on year increase of 7.5 times. With
more production approvals obtained, production of small liquid injections in
ampoule will be realized on a large scale, and become one of the new growth
points of the Company
s results.

innovation capabilities of the Group have been further enhanced. In 2018, the
Company was successively recognized by the National Development and Reform
Commission and other ministries/commissions as the National Enterprise
Technology Centre and by the Ministry of Industry and Information Technology
and the Ministry of Finance as the National Technology Innovation Enterprise.
There have been continuous achievements from new innovations. During the year,
a total of 48 registrations were completed, the Company was granted approval for
generic drug production and registration for a total of 15 drugs, among which
Moxifloxacin Hydrochloride and Sodium Chloride Injection, the first new
antibiotic product approved in China for use in soft bag packaging, was
included in the China National Essential Drug List and will quickly become a
leading product for the growth of the Company’s being performance. In addition,
Hemofiltration Solution and Hemofiltration Basic Replacement Fluid, being the
second in China approved for hemodialysis, will be two crucial products for the
Company to enter the hemofiltration market with plenty of room for market
growth. Balanced Salt Solution (Irrigating) was used in ophthalmic operations
for irrigating and rinsing, and was the first generic product in the domestic
market. The 4 liquid injection products in polypropylene ampoule for small
volume intravenous infusion, including Ambroxol, potassium chloride and sodium
chloride further enriched the Company’s product lines in polypropylene ampoule

the aspect of development of projects, the Company constructed the new
production line for surgical soft bag intravenous infusion solution in sterile
package, and obtained the GMP certification to commence operation during the
year. The production line dedicated for large-volume soft bag infusion is under
construction, and is expected to be ready for production in May 2019. By
speeding up the construction of pharmaceutical research & development
platform and support projects for pilot-run and industrialized production, they
will be ready to use in year 2019. The bulk pharmaceuticals project phase one
focuses on the production of chemical bulk pharmaceuticals such as caffeine.
The overall construction progress of the project has entered the final stage,
and the project is expected to be ready for trial run in April 2019.

Looking ahead for year 2019, under the immensely complex economic
conditions in China and numerous potential adverse factors, the overall
performance of pharmaceutical industry may be affected by uncertainties in
relation to more policy changes brought by
4+7 centralized procurement. In terms of intravenous infusion solution
industry, upon industry consolidation, it is expected the environment in which
stronger side always enjoys superiority remains unchanged, which fosters the
development of leading enterprises. The Company will exert all efforts to
capture the historic growth opportunity by expanding its market share,
improving its product mix, boosting the sales of approved new products and
raising the proportions of the therapeutic infusion solutions in production and
sales. These helps strengthening the Company
s leading position in the intravenous infusion solutions industry.
The annual sales target of intravenous infusion solutions is more than 1,600
million bottles/bags. Sales for new therapeutic products such as Moxifloxacin
Hydrochloride Sodium Chloride Injection, Sodium Acetate Ringer and Ambroxol in
upright soft bags will be realized on a large scale, developing the sales scale
of these therapeutic infusion products to reach the level of RMB100 million,
and become the main driving force for the growth of the Company
s result.

Regarding the research and development of new products, the Company
will adhere to the new products development idea of
combining generic drugs and innovative drugs with injection as the basis. Besides, we will comprehensively
promote the development of the new products for therapeutic injections, and
focus on various fields including treatment of chronic diseases and circulatory
systems, emergency anesthesia therapy, antipyretic and analgesic therapy, as
well as the new anti-infective therapy. We expect to obtain approximately 11
production approvals for injection this year.
The company will accelerate the forming
of Company’s product portfolio in the field of respiratory and kidney disease
and dialysis, gradually establishing its leading position in injections in
terms of high-end drug delivery system and innovative packaging form.
We will also put strenuous efforts in the development of innovative
drugs which are not yet meeting clinical criteria, explore the market in the
area of new respiratory, gradually entered the children
s oral medication market. Meanwhile, the submission of certification
materials for the FDA of the United States will be completed within the year,
to make preparation of development into the international market.

Mr. Qu Jiguang, Chairman and
CEO of SSY Group Limited
said, “We
are full of confidence on the future development of the Company. Leveraging on
the competitive edges on our scale, quality and lean management in the
industry, our leading position in the industry of infusion solution products
will be further strengthened despite strong market competition. We are
committed to bringing satisfactory return to our investors. I would like to
take this opportunity to express our gratitude to our investors and all staff
of the Group for their support to the development of the Company.”

About SSY Group Limited

SSY Group Limited is one of the leading pharmaceutical
manufacturers in China with nearly 7 decades of operation history and a
well-established brand name. The Group went public on the Hong Kong Stock
Exchange in December 2005 with stock code 2005. The group has become a component
stock of Morgan Stanley Capital International Index (MSCI) China Index from
June 2018. The Group is principally engaged in the research, development,
manufacture and sale of a wide range of pharmaceutical products, including OTC
drugs, bulk medicine and medical materials, mainly intravenous infusion
solution to hospital and distributors. The manufacturing plants of the Group
locates in Hebei Province and Jiangsu Province in China, its products take
leading position in the high-end hospital market in China.

Source:: Media Outreach